Antihypertensive profile of 2-thienyl-3,4-methylenedioxybenzoylhydrazone is mediated by activation of the A2A adenosine receptor

European Journal of Medicinal Chemistry

Volumn 55, Issue , 2012, Pages 49-57

  Leal, Carla Moreira ^a   Pereira, Sharlene Lopes ^a   Kümmerle, Arthur Eugen ^b   Leal, Daniella Moreira ^a   Tesch, Roberta ^a   De Sant'Anna, Carlos M R ^b   Fraga, Carlos Alberto M ^a   Barreiro, Eliezer Jesus ^a   Sudo, Roberto Takashi ^a   Zapata Sudo, Gisele ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Adenosine agonist; Antihypertensive; LASSBio 1027; N acylhydrazone; Vasodilator

Indexed keywords

2 THIENYL 3,4 METHYLENEDIOXYBENZOYLHYDRAZONE; 3,4 METHYLENEDIOXYBENZOYL 2 THIENYLHYDRAZONE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2 A RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; GLIBENCLAMIDE; HYDRAZONE DERIVATIVE; LASSBIO 1027; N(G) NITROARGININE METHYL ESTER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HYPERTENSION; MALE; MOLECULAR DOCKING; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; THORACIC AORTA; VASODILATATION; WISTAR KYOTO RAT;

ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DISCOVERY; HEK293 CELLS; HUMANS; HYDRAZONES; MALE; MOLECULAR DOCKING SIMULATION; MUSCLE, SMOOTH, VASCULAR; PROTEIN CONFORMATION; RATS; RECEPTOR, ADENOSINE A2A; RECEPTOR, ADENOSINE A3; THIOPHENES; TIME FACTORS; VASODILATION;

EID: 84865764329     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.06.056     Document Type: Article

References (47)

1. World Health Organization The World Health Report 2002: Reducing Risks, Promoting Healthy Life 2002 World Health Organization Geneva, Switzerland Available at: http://www.who.int/whr/2002/en/ (accessed 19.02.10)
2. A. Mosterd, R.B. D' Agostino, H. Silbershatz, P.A. Sytkowski, W.B. Kannel, and D.E. Grobbee Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989 N. Engl. J. Med. 340 1999 1221 1227
3. P.M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P.K. Whelton, and J. He Global burden of hypertension: analysis of worldwide data Lancet 365 2005 217 223
4. M. Pereira, N. Lunet, and A. Azevedo Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries J. Hypertens. 27 2009 963 975
5. American Heart Association Cardiovascular diseases in the United States: 2009 Available at: www.yourethecure.org (accessed 21.01.11)
6. E.J. Barreiro Estratégia de simplificação molecular no planejamento racional de fármacos: A descoberta de novo agente cardioativo Quim. Nova 25 2002 1172 1180
7. R.T. Sudo, G. Zapata-Sudo, and E.J. Barreiro The new compound, LASSBio 294, increases the contractility of intact and saponin-skinned cardiac muscle from Wistar rats Br. J. Pharmacol. 134 2001 603 613
8. C.L.M. Silva, F. Noel, and E.J. Barreiro Cyclic GMP-dependent vasodilatory properties of LASSBio 294 in rat aorta Br. J. Pharmacol. 135 2002 293 298
9. A.G. Silva, G. Zapata-Sudo, A.E. Kummerle, C.A. Fraga, E.J. Barreiro, and R.T. Sudo Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues Bioorg. Med. Chem. 13 2005 3431 3437
10. S. Yamada, D. Morizono, and K. Yamamoto Mild oxidation of aldehydes to the corresponding carboxylic acids and esters: alkaline iodine oxidation revisited Tetrahedron Lett. 33 1992 4329 4332
11. P.C. Lima, L.M. Lima, K.C.M. da Silva, P.H.O. Léda, A.L.P. de Miranda, C.A.M. Fraga, and E.J. Barreiro Synthesis and analgesic activity of novel N-acylarylhydrazones and isosters, derived from natural safrole Eur. J. Med. Chem. 35 2000 187 203
12. C.A.M. Fraga, and E.J. Barreiro Medicinal chemistry of N-acylhydrazones: new lead-compounds of analgesic, antiinflammatory and antithrombotic drugs Curr. Med. Chem. 13 2006 167 198
13. A.E. Kümmerle, J.M. Raimundo, C.M. Leal, G.S. da Silva, T.L. Balliano, M.A. Pereira, C.A. de Simone, R.T. Sudo, G. Zapata-Sudo, C.A.M. Fraga, and E.J. Barreiro Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives Eur. J. Med. Chem. 44 2009 4004 4009
14. M.C. Peitsch Protein modeling by E-mail Nat. Biotechnol. 13 1995 658 660
15. K. Arnold, L. Bordoli, J. Kopp, and T. Schwede The SWISS-MODEL workspace: a web-based environment for protein structure homology modeling Bioinformatics 22 2006 195 201
16. B.B. Fredholm, A.P. Ijzerman, K.A. Jacobson, K. Klotz, and J. Linden International Union of Pharmacology XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 53 2001 527 552
17. M.E. Olah, and G.L. Stiles Adenosine receptor subtypes: characterization and therapeutic regulation Annu. Rev. Pharmacol. Toxicol. 35 1995 581 606
18. R.A. Olsson, and J.D. Pearson Cardiovascular purinoceptors Physiol. Rev. 70 1990 761 845
19. R.L. Webb, R.B. Mcneal Jr., B.W. Barclay, and G.D. Yasay Hemodynamic effects of adenosine agonists in the conscious spontaneously hypertensive rat J. Pharmacol. Exp. Ther. 254 1990 1090 1099
20. J.C. Shryock, and L. Belardinelli Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology Am. J. Cardiol. 79 1997 2 10
21. C.D. Lewis, S.M. Hourani, C.J. Long, and M.G. Collis Characterization of adenosine receptors in the rat isolated aorta Gen. Pharmacol. 25 1994 1381 1387
22. D.J. Prentice, and S.M. Hourani Activation of multiple sites by adenosine analogues in the rat isolated aorta Br. J. Pharmacol. 118 1996 1509 1517
23. 3 adenosine receptor targeting agents Expert Opin. Investig. Drugs 20 2011 757 768
24. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury Am. J. Physiol. Heart Circ. Physiol. 283 2002 H1307 H1313
25. 3 receptor agonist, IB-MECA Eur. J. Pharmacol. 477 2003 235 245
26. 3 adenosine receptor and inflammation Front. Immunol. 3 2012 1 12
27. S. Leal, C. Sá, J. Gonçalves, P. Fresco, and C. Diniz Immunohistochemical characterization of adenosine receptors in rat aorta and tail arteries Microsc. Res. Tech. 71 2008 703 709
28. U. Ikeda, K. Kurosaki, K. Ohya, and K. Shimada Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells Cardiovasc. Res. 35 1997 168 174
29. C.J. Ray, and J.M. Marshall The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium J. Physiol. 570 2006 85 96
30. + channels in vascular smooth muscle cells J. Smooth Muscle Res. 44 2008 65 81
31. R.K. Dubey, Z. Mi, D.G. Gillespie, and E.K. Jackson Dysregulation of extracellular adenosine levels by vascular smooth muscle cells from spontaneously hypertensive rats Arterioscler. Thromb. Vasc. Biol. 21 2001 249 254
32. R.K. Dubey, E.K. Jackson, H. Rupperecht, and R.B. Sterzel Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells Curr. Opin. Nephrol. Hypertens. 6 1997 88 105
33. R.K. Dubey, D.G. Gillespie, Z. Mi, F. Suzuki, and E.K. Jackson Smooth muscle cell derived adenosine inhibits cell growth Hypertension 27 1996 766 773
34. 2 receptors Eur. J. Pharmacol. 196 1991 69 76
35. C. Casati, A. Monopoli, A. Forlani, E. Bonizzoni, and E. Ongini Telemetry monitoring of hemodynamic effects induced over time by adenosine agonists in spontaneously hypertensive rats J. Pharmacol. Exp. Ther. 275 1995 914 919
36. 2A adenosine agonists Hypertension 25 1995 564 569
37. 2A receptor agonist Nucleosides Nucleotides 18 1998 2175 2191
38. E. Camaioni, E. Di Francesco, S. Vittori, R. Volpini, and G. Cristalli Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA Bioorg. Med. Chem. 5 1997 2267 2275
39. C. Sala, A. Monopoli, C. Alberti, C. Casati, E. Ongini, A. Zanchetti, and A. Morganti Humoral effects of selective adenosine agonists in spontaneously hypertensive rats J. Hypertens. 14 1996 75 79
40. 2A agonists upon chronic administration J. Pharmacol. Exp. Ther. 267 1993 287 295
41. G. Zapata-Sudo, S.L. Pereira, H.J.V. Beiral, A.E. Kümmerle, J.M. Raimundo, and F. Antunes Pharmacological characterization of (3-thienylidene)-3,4-methylenedioxybenzoylhydrazide: a novel muscarinic agonist with antihypertensive profile Am. J. Hypertens. 23 2010 135 141
42. C.J. Ray, M.R. Abbas, A.M. Coney, and J.M. Marshall Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies J. Physiol. 544 2002 195 209
43. X.M. Zhu, L.H. Fang, Y.J. Li, and G.H. Du Endothelium-dependent and independent relaxation induced by pinocembrin in rat aortic rings Vascul. Pharmacol. 46 2007 160 165
44. J. Duarte, F. Perez-Vizcaino, A.I. Torres, A. Zarzuelo, J. Jimenez, and J. Tamargo Vasodilator effects of visnagin in isolated vascular smooth muscle Eur. J. Pharmacol. 286 1995 115 122
45. 2A adenosine receptor bound to an antagonist Science 322 2008 1211 1217
46. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
47. M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, and J.J.P. Stewart Development and use of quantum mechanical molecular models 76. AM1: a new general purpose quantum mechanical molecular model J. Am. Chem. Soc. 107 1985 3902 3909